Salez F, Lamblin C, Wallaert B
Clinique des Maladies Respiratoires, Hopital A.-Calmette, Lille.
Rev Mal Respir. 2000 Feb;17(1 Pt 2):265-78.
Allergic bronchopulmonary aspergillosis (ABPA) is an immunologic bronchopulmonary inflammation due to an immune response of the lower respiratory tract against Aspergillus fumigatus. The major clinical features of ABPA include asthma, recurrent pulmonary infiltrates, immediate wheal and flare skin reactivity to A. fumigatus, elevated total serum IgE levels, detectable serum precipitating antibodies to A. fumigatus, peripheral blood eosinophilia, elevated levels of Aspergillus-specific serum IgE and central bronchiectasis with normal distal structures. The diagnosis of ABPA should be considered in asthmatics of all ages. Evolution of the disease comprises five stages from the acute to the fibrotic stage including pulmonary fibrosis and respiratory insufficiency. The goals of ABPA treatment are to control patient's asthma and prevent exacerbations of ABPA. During the acute stage, prednisone should be administered. Antifungals agents (itraconazole) may be useful to prevent exacerbations of the disease.
变应性支气管肺曲霉病(ABPA)是一种由于下呼吸道对烟曲霉产生免疫反应而导致的免疫性支气管肺炎症。ABPA的主要临床特征包括哮喘、反复肺部浸润、对烟曲霉立即出现风团及潮红皮肤反应、血清总IgE水平升高、可检测到的针对烟曲霉的血清沉淀抗体、外周血嗜酸性粒细胞增多、烟曲霉特异性血清IgE水平升高以及中央型支气管扩张而远端结构正常。各年龄段的哮喘患者均应考虑ABPA的诊断。该疾病的演变包括从急性期到纤维化期的五个阶段,包括肺纤维化和呼吸功能不全。ABPA治疗的目标是控制患者的哮喘并预防ABPA的加重。在急性期,应给予泼尼松治疗。抗真菌药物(伊曲康唑)可能有助于预防疾病的加重。